What Is DHEA (Dehydroepiandrosterone)?
Dehydroepiandrosterone, commonly abbreviated DHEA, is an endogenous C19 steroid hormone and a major intermediate in human steroidogenesis. It is synthesized mainly in the zona reticularis of the adrenal cortex from cholesterol, although smaller amounts are produced in the gonads, skin, and nervous system. Adrenal cholesterol is converted through pregnenolone and 17-hydroxypregnenolone to DHEA by the enzymes CYP11A1, CYP17A1, and related hydroxysteroid dehydrogenases. DHEA is often described as an androgen precursor because peripheral tissues can convert it to androstenedione, testosterone, dihydrotestosterone, estrone, and estradiol. It is not, however, simply a circulating form of testosterone: its biological effects vary with tissue-specific enzymes, receptor expression, age, sex, and local conversion pathways.
DHEA secretion rises during adrenarche, increases through adolescence, and generally reaches its highest circulating concentration during the second or third decade of life. Thereafter, levels decline progressively, often reaching approximately 10-20% of young-adult concentrations by the seventh or eighth decade. This age-associated fall is sometimes called adrenopause, although it is not a universally accepted clinical diagnosis and does not necessarily represent a disease state. Most circulating DHEA is rapidly sulfated by steroid sulfotransferase to form DHEA sulfate, or DHEA-S. DHEA-S is generally present at concentrations roughly tenfold higher than free DHEA and has a substantially longer half-life, making it a more stable clinical marker of adrenal androgen production. DHEA can also be synthesized locally in the brain, where it and DHEA-S act as neurosteroids. Research on DHEA expanded notably during the 1980s and 1990s as investigators explored aging, immune function, mood, and sexual physiology. The 2000s brought larger randomized trials and more critical reviews, and contemporary work focuses on carefully defined deficiencies, vaginal prasterone, tissue-specific actions, and the distinction between biochemical associations and clinically meaningful benefits.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Dehydroepiandrosterone replacement in women with adrenal insufficiency
Arlt, W., Callies, F., van Vlijmen, J. C., et al., 1999, New England Journal of Medicine - DHEA in elderly women and DHEA or testosterone in elderly men
Nair, K. S., Rizza, R. A., O'Brien, P., et al., 2006, New England Journal of Medicine - Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue
Baulieu, E. E., Thomas, G., Legrain, S., et al., 2000, Proceedings of the National Academy of Sciences of the United States of America - Dehydroepiandrosterone replacement in women with adrenal insufficiency: a randomized trial
Gurnell, E. M., Hunt, P. J., Curran, S. E., et al., 2008, Journal of Clinical Endocrinology and Metabolism - Dehydroepiandrosterone for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials
Peixoto, C., Devicari, C., Fuchs, T., et al., 2014, Journal of Affective Disorders